These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32303561)

  • 1. ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.
    Zhu J; Tian X; Shehu AI; McMahon DK; Ma X
    J Pharmacol Exp Ther; 2020 Jul; 374(1):38-43. PubMed ID: 32303561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.
    Elliot ER; Neary M; Else L; Khoo S; Moyle G; Carr DF; Wang X; Mcclure M; Boffito M; Owen A
    J Antimicrob Chemother; 2020 May; 75(5):1259-1266. PubMed ID: 32011683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.
    Spector SA; Brummel SS; Chang A; Wiznia A; Ruel TD; Acosta EP;
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):297-303. PubMed ID: 38180896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
    Enoki Y; Kishi N; Sakamoto K; Uchiyama E; Hayashi Y; Suzuki N; Ito M; Taguchi K; Yokoyama Y; Kizu J; Matsumoto K
    Drug Metab Pharmacokinet; 2021 Apr; 37():100371. PubMed ID: 33556698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abcg2 transporter affects plasma, milk and tissue levels of meloxicam.
    Garcia-Lino AM; Blanco-Paniagua E; Astorga-Simon EN; Alvarez-Fernandez L; Garcia-Mateos D; Alvarez-Fernandez I; Alvarez AI; Merino G
    Biochem Pharmacol; 2020 May; 175():113924. PubMed ID: 32217099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].
    Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T
    Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
    Castellino S; Moss L; Wagner D; Borland J; Song I; Chen S; Lou Y; Min SS; Goljer I; Culp A; Piscitelli SC; Savina PM
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3536-46. PubMed ID: 23669385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.
    Bade AN; McMillan JM; Liu Y; Edagwa BJ; Gendelman HE
    Mol Neurobiol; 2021 Nov; 58(11):5703-5721. PubMed ID: 34390469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
    McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.
    Kirkwood-Johnson L; Katayama N; Marikawa Y
    Toxicol Sci; 2021 Nov; 184(2):191-203. PubMed ID: 34515794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
    Martínez-Chávez A; Broeders J; Lebre MC; Tibben MT; Rosing H; Beijnen JH; Schinkel AH
    Eur J Pharm Sci; 2021 Apr; 159():105740. PubMed ID: 33524505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
    Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature.
    Li J; Yusuf EH; Agwu AL
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):373-375. PubMed ID: 32448908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
    Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
    Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.